Anticancer Res. 2011 Apr;31(4):1417-20.

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL.

Source

M.D. Anderson Cancer Center, Houston, TX 77030, USA. dfogelman@mdanderson.org

Abstract

Pancreatic cancer is an aggressive, frequently fatal malignancy that strikes 37,000 patients annually in the U.S.A. It is poorly responsive to standard chemotherapies such as gemcitabine. Approximately 5-10% of pancreatic cancer occurs in the setting of a BRCA2 mutation. Breast and ovarian carcinomas that harbor BRCA2 mutations are susceptible to the effects of an emerging class of targeted agents, namely, poly(ADP-ribose) polymerase (PARP) inhibitors. This report describes the case of a patient with a germline BRCA2 mutation and an associated pancreatic cancer treated with iniparib (BSI-201), a PARP inhibitor, who demonstrated a complete pathologic response to this agent. This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer.

PMID:: 21508395; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

HighWire Press

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. [Int J Biol Sci. 2006]
The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, et al. Int J Biol Sci. 2006; 2(4):179-85. Epub 2006 Jun 10.
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. [Nature. 2008]
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, et al. Nature. 2008 Feb 28; 451(7182):1116-20. Epub 2008 Feb 10.
Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. [Cancer Biol Ther. 2005]
Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition.
Gallmeier E, Kern SE. Cancer Biol Ther. 2005 Jul; 4(7):703-6. Epub 2005 Jul 10.
Review Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. [IDrugs. 2010]
Review Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer.
Liang H, Tan AR. IDrugs. 2010 Sep; 13(9):646-56.
Review The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. [Asia Pac J Clin Oncol. 2011]
Review The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL. Asia Pac J Clin Oncol. 2011 Sep; 7(3):197-211.

See reviews... See all...

Cited by 1 PubMed Central article

Drug therapy for hereditary cancers. [Hered Cancer Clin Pract. 2011]
Drug therapy for hereditary cancers.
Imyanitov EN, Moiseyenko VM. Hered Cancer Clin Pract. 2011 Aug 6; 9(1):5. Epub 2011 Aug 6.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated p...
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
Anticancer Res. 2011 Apr ;31(4):1417-20.

PubMed
HIV-1 vaccines and adaptive trial designs.
HIV-1 vaccines and adaptive trial designs.
Sci Transl Med. 2011 Apr 20 ;3(79):79ps13.

PubMed
Dietary intakes of arachidonic acid and alpha-linolenic acid are associated with...
Dietary intakes of arachidonic acid and alpha-linolenic acid are associated with reduced risk of hip fracture in older adults.
J Nutr. 2011 Jun ;141(6):1146-53. Epub 2011 Apr 20 .

PubMed
Causes and prevention of herb-induced aconite poisonings in Asia.
Causes and prevention of herb-induced aconite poisonings in Asia.
Hum Exp Toxicol. 2011 Dec ;30(12):2023-6. Epub 2011 Apr 20 .

PubMed
Analysis of HIV-1 expression level and sense of transcription by high-throughput...
Analysis of HIV-1 expression level and sense of transcription by high-throughput sequencing of the infected cell.
J Virol. 2011 Jul ;85(13):6205-11. Epub 2011 Apr 20 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 1 PubMed Central article

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information